Drug Profile
Lifileucel - Iovance Biotherapeutics
Alternative Names: AMTAGVI; Autologous TILs - Iovance Biotherapeutics; Contego™ - Iovance Biotherapeutics; LN-144; Tumour infiltrating lymphocytes - Iovance BiotherapeuticsLatest Information Update: 11 Mar 2024
Price :
$50
*
At a glance
- Originator Genesis Biopharma
- Developer Iovance Biotherapeutics
- Class Antineoplastics; Cell therapies; Immunotherapies; Tumour infiltrating lymphocyte therapies
- Mechanism of Action Immunologic cytotoxicity; Lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Registered Malignant melanoma
- Phase I Uveal melanoma
Most Recent Events
- 11 Mar 2024 Iovance Biotherapeutic plans to initiate a Clinical trial for Endometrial cancer
- 28 Feb 2024 Iovance Biotherapeutics announces intention for Regulatory submission for Malignant melanoma in Australia and other countries in 2025
- 16 Feb 2024 Registered for Malignant melanoma (Inoperable/Unresectable, Metastatic disease, Second-line therapy or greater) in USA (IV) - First global approval